A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)
Clinical trial NCT06389799 · RECRUITING
Trial details
- NCT number
- NCT06389799
- Sponsor
- Lund University Hospital
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2024-06-20
- Primary completion
- 2027-12-31
- Enrollment
- 33
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.